New insights on brain-spinal communication in opioid withdrawal lead to a clinical trial
A new clinical trial at the University of Calgary uses probenecid, a gout drug, to help with opioid withdrawal symptoms, based on research showing it reduces withdrawal in rodents by disrupting abnormal brain-spinal cord communication during withdrawal.
Reference News
New insights on brain-spinal communication in opioid withdrawal lead to a clinical trial
A new clinical trial at the University of Calgary uses probenecid, a gout drug, to help with opioid withdrawal symptoms, based on research showing it reduces withdrawal in rodents by disrupting abnormal brain-spinal cord communication during withdrawal.
Insights on brain-spinal communication in opioid withdrawal lead to a clinical trial
A clinical trial at the University of Calgary uses an anti-gout medication, probenecid, to address severe opioid withdrawal symptoms, based on insights into brain-spinal communication during withdrawal.